Efficacy and safety of antiviral plus anti-spike monoclonal antibody combination therapy versus monotherapy for high-risk immunocompromised patients with mild to moderate SARS-CoV2 infection during Omicron era. A prospective cohort study
Description
CONCLUSIONS: In immunocompromised, combination therapy including sotrovimab plus an antiviral may be more effective than monotherapy for SARS-CoV2.
